Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Antonioli

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
Journal of Caffeine and Adenosine Research|November 21, 2019
Caffeine and Bones: If Less Is Good, More May Not Be BetterLuca Antonioli, György Haskó
Purinergic Signalling|May 2, 2022
May be adenosine an immuno-quorum-sensing signal?Luca Antonioli, György Haskó
Trends in Pharmacological Sciences|December 20, 2016
A Purinergic Trail for MetastasesDavide Ferrari, Fabio Malavasi, Luca Antonioli
Alimentary Pharmacology & Therapeutics|September 5, 2020
Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?Lorenzo Bertani, Luca Antonioli, Corrado Blandizzi
Trends in Pharmacological Sciences|November 15, 2021
Adenosine and inflammation: it's time to (re)solve the problemLuca Antonioli, Pál Pacher, György Haskó
Neuropharmacology|May 19, 2015
Enteric purinergic signaling: Shaping the "brain in the gut"Luca Antonioli, Corrado Blandizzi, Maria Cecilia Giron
Biochemical Pharmacology|February 11, 2018
Adenosine metabolism, immunity and joint healthGyörgy Haskó, Luca Antonioli, Bruce N Cronstein
Purinergic Signalling|February 20, 2024
Preclinical and clinical aspects of P2X receptors as a common route in different diseases: A meeting reportLuke Tattersall, Elena Adinolfi, Luca Antonioli, et al.
Alimentary Pharmacology & Therapeutics|October 29, 2020
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' replyLorenzo Bertani, Matteo Fornai, Luca Antonioli, et al.
Oncoimmunology|May 4, 2016
Myeloid cells in the tumor microenvironment: Role of adenosineSilvana Morello, Aldo Pinto, Corrado Blandizzi, et al.
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
Journal of Caffeine and Adenosine Research|November 21, 2019
Caffeine and Bones: If Less Is Good, More May Not Be BetterLuca Antonioli, György Haskó
Purinergic Signalling|May 2, 2022
May be adenosine an immuno-quorum-sensing signal?Luca Antonioli, György Haskó
Trends in Pharmacological Sciences|December 20, 2016
A Purinergic Trail for MetastasesDavide Ferrari, Fabio Malavasi, Luca Antonioli
Alimentary Pharmacology & Therapeutics|September 5, 2020
Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?Lorenzo Bertani, Luca Antonioli, Corrado Blandizzi
Trends in Pharmacological Sciences|November 15, 2021
Adenosine and inflammation: it's time to (re)solve the problemLuca Antonioli, Pál Pacher, György Haskó
Neuropharmacology|May 19, 2015
Enteric purinergic signaling: Shaping the "brain in the gut"Luca Antonioli, Corrado Blandizzi, Maria Cecilia Giron
Biochemical Pharmacology|February 11, 2018
Adenosine metabolism, immunity and joint healthGyörgy Haskó, Luca Antonioli, Bruce N Cronstein
Purinergic Signalling|February 20, 2024
Preclinical and clinical aspects of P2X receptors as a common route in different diseases: A meeting reportLuke Tattersall, Elena Adinolfi, Luca Antonioli, et al.
Alimentary Pharmacology & Therapeutics|October 29, 2020
Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' replyLorenzo Bertani, Matteo Fornai, Luca Antonioli, et al.
Oncoimmunology|May 4, 2016
Myeloid cells in the tumor microenvironment: Role of adenosineSilvana Morello, Aldo Pinto, Corrado Blandizzi, et al.
Pageof 18